Kawasaki disease (KD), which occurs mostly in infants and young children, is a vasculitis syndrome of unknown etiology and is a common acute, febrile, rash disease in pediatrics. Kawasaki disease generally resolves spontaneously after the acute phase and has a certain recurrence rate, but the recurrence rate is low, only 1%-3%, and is usually judged based on clinical manifestations and corresponding ancillary tests. The main manifestations of Kawasaki disease are persistent fever for more than 5 days, bulbar conjunctival congestion, lip and oral changes, nonsuppurative superficial lymphadenitis, rash, terminal sclerosis and membranous desquamation of the extremities. If the clinical symptoms and signs of the initial onset disappear for more than 2 months, i.e., after the abnormal laboratory test indexes of the initial onset, such as white blood cell count, platelets, C-reactive protein and blood sedimentation, have completely returned to normal, having 5 of the above 6 items, Kawasaki disease is considered to have relapsed. There is no specific therapy for Kawasaki disease, and the focus of treatment is to control vasculitis early and prevent the occurrence of coronary artery damage. Anti-inflammatory and anticoagulant therapy should still be intensified in recurrent cases. After giving gammaglobulin combined with aspirin, if the effect is not satisfactory, then hormone therapy can be added, and if necessary, biological agents can be applied to achieve good results.